centerforbiosimilars1h
Eye on Pharma: Korean Drugmakers’ Impact in Europe; New Denosumab, Eculizumab Deals
Korean drugmakers hold over 50% market share in the 6 best-selling biosimilar markets, 2 companies sign exclusive licensing ...
Samsung Bioepis, Teva Enter License, Development, Commercialization Agreement For EPYSQLI
Samsung Bioepis Co. and Teva Pharmaceutical Industries (TEVA have entered into a license, development and commercialization agreement ...
manilatimes23h
Samsung Bioepis and Teva Enter into a Strategic Partnership for Commercialization of EPYSQLI® (eculizumab-aagh) in the United States
Under the terms of the agreement, Samsung Bioepis will be responsible for the development, regulatory registration, ...